Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $615000.0.

  • Heron Therapeutics' Depreciation & Amortization (CF) rose 585.2% to $615000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year decrease of 993.53%. This contributed to the annual value of $2.5 million for FY2024, which is 1379.31% down from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Depreciation & Amortization (CF) is $615000.0, which was up 585.2% from $611000.0 recorded in Q2 2025.
  • Heron Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $794000.0 during Q4 2021, with a 5-year trough of $551000.0 in Q1 2025.
  • Its 5-year average for Depreciation & Amortization (CF) is $688789.5, with a median of $716000.0 in 2023.
  • In the last 5 years, Heron Therapeutics' Depreciation & Amortization (CF) surged by 1900.16% in 2021 and then crashed by 2008.25% in 2024.
  • Over the past 5 years, Heron Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $794000.0 in 2021, then decreased by 0.38% to $791000.0 in 2022, then decreased by 9.48% to $716000.0 in 2023, then fell by 17.74% to $589000.0 in 2024, then grew by 4.41% to $615000.0 in 2025.
  • Its Depreciation & Amortization (CF) stands at $615000.0 for Q3 2025, versus $611000.0 for Q2 2025 and $551000.0 for Q1 2025.